Used for the assessment of metabolic stability of drug candidates and identification of breakdown products
Post author: Andrew Powell. Last update: 13/03/2014 at 12:02 pm by Andrew Powell.
Rapid metabolism is a major limiting feature of many new drug candidates and can lead to low oral bioavailability, a short in vivo half-life, or the production of potentially active or toxic metabolites. The CDCO uses a range of in vitro assays to assess the metabolism of compounds during early lead optimisation through to candidate selection. Metabolite characterisation studies are performed to identify major metabolic products and metabolising enzymes, identify metabolically labile functional moieties within a series, and assess the potential for metabolic drug-drug interactions.
Operation: Facility provides the service for you
Access: Access by collaboration, Access by fee for service, Access by users external to managing organisation, Access by users internal to managing organisationCapacity: We encourage greater utilisation